HC Wainwright & Co. Initiates Coverage On Predictive Oncology with Buy Rating, Announces Price Target of $3
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on Predictive Oncology (NASDAQ:POAI) with a Buy rating and set a price target of $3.
August 19, 2024 | 10:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on Predictive Oncology with a Buy rating and set a price target of $3.
The initiation of coverage with a Buy rating and a price target of $3 by a reputable analyst firm like HC Wainwright & Co. is likely to positively impact the stock price of Predictive Oncology in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100